AI Article Synopsis
- Recent advancements have led to the identification of key molecules in cancer progression, paving the way for targeted therapies like monoclonal antibodies and small molecules.
- Over the past 15 years, these specific treatments have significantly improved outcomes for certain cancer patients, despite issues with drug resistance.
- The development of biomarkers has enhanced the selection process for patients eligible for these molecular-targeted therapies, marking a significant step in personalized medicine.
Article Abstract
Recently, discovery and identification of critical molecules responsible for cancer progression lead to development of specific target-directed therapies, including monoclonal antibodies and small molecular compounds. For the past 15 years, the advent of target-specific therapeutics has remarkably improved the clinical outcomes of certain patients with various malignancies, and it was followed by the understanding of mechanism of the drug resistance. Moreover, useful biomarkers were developed to further increase the power of patient selection for molecular-targeted therapy. From the historical point of view, we review the progress in developing new molecular-targeted drugs for personalized medicine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!